Trial | NCT01712295  Report issue

Title

17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts
New Formulation of Salicylate to Improve Treatment of Common Skin Warts

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Indication/Condition

    Warts

  • Study Participants

    100
Plantar warts on the sole of the foot are among the most common warts seen in podiatry clinics. Some patients are readily cured by simple standard of care treatments that include wart debridement (trimming or excision) and application of 17% salicylate (commercially known as Compound W)or by other treatments that may be painful and affect mobility. No treatment is consistently effective and most patients fail treatment multiple times.

Ethyl pyruvate (EP)is a common food additive noted to be 'generally regarded as safe' that may improve the activity of salicylate in wart treatment by improving the ability to penetrate and/or persist in the skin. The use of 17% salicylate with the addition of EP may improve cures of common foot plantar warts in subjects who also be receiving other standard-of-care treatment.
Study Started
Nov 30
2011
Primary Completion
Dec 31
2013
Anticipated
Study Completion
Mar 31
2014
Anticipated
Last Update
Oct 23
2012
Estimate

Drug 17% Salicylate with ethyl pyruvate

  • Other names: Compound W

Drug Salicylates

17% Salicylate with Ethyl Pyruvate Experimental

Subjects with plantar wart(s) will apply the product to warts twice a day for up to 16 weeks.

17% salicylate Active Comparator

subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks

Criteria 

Inclusion Criteria:

evidence of skin plantar wart(s)

Exclusion Criteria:

iodine allergy
No Results Posted